Trial Profile
A Phase I Dose-Finding Study of E7050 Administered Orally to Patients With Advanced Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Dec 2017
Price :
$35
*
At a glance
- Drugs Golvatinib (Primary)
- Indications Gastric cancer; Solid tumours
- Focus Adverse reactions; Biomarker
- 05 Apr 2012 Actual patient number changed from 8 to 16 as reported by ClinicalTrials.gov.
- 02 Aug 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
- 02 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.